Pycnogenol® in chronic venous insufficiency

Arcangeli, P

doi:10.1016/s0367-326x(99)00164-1

Cited by 49 publications

(32 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two recent placebo-controlled double-blind clinical trials on CVI corroborate the positive findings on Pycnogenol 1 shown in this study (Arcangeli 2000;Petrassi et al, 2000). These studies also found a significant improvement of CVI-related symptoms.…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Comparative study of Venostasin� and Pycnogenol� in chronic venous insufficiency

Koch¹

2002

Phytother. Res.

View full text Add to dashboard Cite

The aim of this study was to compare the efficacy of Venostasin (horse chestnut seed extract) and Pycnogenol (French maritime pine bark extract) in the treatment of chronic venous insufficiency (CVI). In an open, controlled comparative study 40 patients with diagnosed CVI were treated either with 600 mg chestnut seed extract per day or 360 mg Pycnogenol per day over a period of 4 weeks. The following parameters were investigated before the start of treatment and after 2 and 4 weeks of treatment: circumference of the lower legs and rating of subjective symptoms (scores) of pain, cramps, night-time swelling, feeling of "heaviness", and reddening of the skin. In addition, blood levels of cholesterol LDL and HDL were determined before and at the end of treatment. Pycnogenol significantly reduced the circumference of the lower limbs and significantly improved subjective symptoms. Furthermore, Pycnogenol significantly decreased cholesterol and LDL values in the blood, whereas HDL remained unaffected. Venostasin only moderately but not significantly, reduced the circumference of the lower limbs and marginally improved symptoms. Venostasin had no influence on the determined lipid values. Both medications were equally well tolerated. In conclusion, Pycnogenol was found to be more efficacious than Venostasin for the treatment of CVI.

show abstract

Section: Discussionsupporting

confidence: 88%

“…In a number of clinical trials CVI has been successfully treated with Pycnogenol 1 (Arcangeli, 2000;Petrassi et al, 2000, Gulati, 1999, for a review).…”

mentioning

confidence: 99%

Comparative study of Venostasin� and Pycnogenol� in chronic venous insufficiency

Koch¹

2002

Phytother. Res.

View full text Add to dashboard Cite

show abstract

“…The results of the routine blood examination and urinalysis observed in the present study confirm the results observed in earlier clinical studies (Arcangeli, 2000;Petrassi et al, 2000;Spadea and Balestrazzi, 2001) and demonstrate that Pycnogenol 1 is safe as a food supplement.…”

Section: Melasma and Pycnogenolsupporting

confidence: 91%

Treatment of melasma with Pycnogenol®

Ni¹,

Mu²,

Gulati³

2002

Phytotherapy Research

122

View full text Add to dashboard Cite

Melasma (or chloasma) is a common disorder of cutaneous hyperpigmentation predominantly affecting sun-exposed areas in women. The pathogenesis of melasma is not fully understood and treatments are frequently disappointing and often associated with side effects. Pycnogenol is a standardized extract of the bark of the French maritime pine (Pinus pinaster), a well-known, potent antioxidant. Studies in vitro show that Pycnogenol is several times more powerful than vitamin E and vitamin C. In addition, it recycles vitamin C, regenerates vitamin E and increases the endogenous antioxidant enzyme system. Pycnogenol protects against ultraviolet (UV) radiation. Therefore its efficacy in the treatment of melasma was investigated. Thirty women with melasma completed a 30-day clinical trial in which they took one 25 mg tablet of Pycnogenol with meals three times daily, i.e. 75 mg Pycnogenol per day. These patients were evaluated clinically by parameters such as the melasma area index, pigmentary intensity index and by routine blood and urine tests. After a 30-day treatment, the average melasma area of the patients decreased by 25.86 +/- 20.39 mm(2) (p < 0.001) and the average pigmentary intensity decreased by 0.47 +/- 0.51 unit (p < 0.001). The general effective rate was 80%. No side effect was observed. The results of the blood and urine test parameters at baseline and at day 30 were within the normal range. Moreover, several other associated symptoms such as fatigue, constipation, pains in the body and anxiety were also improved. To conclude, Pycnogenol was shown to be therapeutically effective and safe in patients suffering from melasma.

show abstract

“…Five placebo-controlled, double-blind studies involving a total of 149 patients and three double-blind, controlled studies in a total of 231 patients have demonstrated that Pycnogenol ® significantly improved pain, occurrence of cramps, heaviness of legs and significantly reduced swelling in the lower leg and ankle (Gulati, 1999). Two independent studies with 40 patients each confirmed the efficacy of Pycnogenol ® in chronic venous insufficiency (Arcangeli, 2000;Petrassi et al, 2000). Another blind study compared the effects of horse chestnut seed extract and Pycnogenol ® by measuring the circumference of the lower limb in patients with CVI.…”

Section: Clinical Experience With Pycnogenol ®mentioning

confidence: 90%

Zinopin^® – the rationale for its use as a food supplement in traveller's thrombosis and motion sickness

Scurr

Gulati

2004

Phytotherapy Research

View full text Add to dashboard Cite

Venous thrombo-embolism (VTE) has been associated with periods of prolonged immobility during air, sea and road travel. Motion sickness (MS) has also been reported during both long and short journeys. Current prophylactic therapies for both these indications are generally associated with side effects. Physiological profiles of Pycnogenol and Standardized Ginger Root Extract (SGRE) representing active constituents of Zinopin have been described and reviewed in relation to their activities involved in the patho-physiology of VTE (Traveller's Sickness) and MS and their safe use as food supplement, in traveller's thrombosis and motion sickness. The pathophysiology of VTE and MS is discussed in light of epidemiological data and risk factors associated with these conditions. Rationale of development of Zinopin and its mechanism of action are discussed based on physiological synergy of Pycnogenol and SGRE. Conclusions are made in light of preliminary clinical findings obtained in an open controlled clinical trial. Further clinical study on Zinopin on these lines is suggested.

show abstract

Pycnogenol® in chronic venous insufficiency

Cited by 49 publications

References 10 publications

Comparative study of Venostasin� and Pycnogenol� in chronic venous insufficiency

Comparative study of Venostasin� and Pycnogenol� in chronic venous insufficiency

Treatment of melasma with Pycnogenol®

Zinopin^® – the rationale for its use as a food supplement in traveller's thrombosis and motion sickness

Contact Info

Product

Resources

About

Pycnogenol® in chronic venous insufficiency

Cited by 49 publications

References 10 publications

Comparative study of Venostasin� and Pycnogenol� in chronic venous insufficiency

Comparative study of Venostasin� and Pycnogenol� in chronic venous insufficiency

Treatment of melasma with Pycnogenol®

Zinopin® – the rationale for its use as a food supplement in traveller's thrombosis and motion sickness

Contact Info

Product

Resources

About

Zinopin^® – the rationale for its use as a food supplement in traveller's thrombosis and motion sickness